Edwards Lifesciences (EW)
Healthcare · NYSE · US
Price as at 30 Sept 2026, 21:38 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Edwards Lifesciences trades at $86.32, which is 55% above the $38.48 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 76 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 49.8 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
EW earnings and analyst estimates
Recommendation mix, 29 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
EW passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
18 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$513.57M · 0.2% of book
- Ken Griffin, CITADEL ADVISORS LLC$361.65M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$324.28M · 0.1% of book
- Steve Cohen, Point72 Asset Management, L.P.$160.49M · 0.2% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$137.67M · 0.1% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in EW
We hold 6 disclosed trades in EW by members of Congress and executive-branch officials. The latest 5:
- Donald J Trump · Executive branchBuy · $50,001 - $100,000 · traded 11 May 2026 · disclosed 1 Jul 2026
- Alan Armstrong · SenateBuy · $1,001 - $15,000 · traded 27 Mar 2026 · disclosed 21 Jul 2026
- Bruce Westerman · HouseSell · $1,001 - $15,000 · traded 21 Apr 2025 · disclosed 12 May 2025
- Bruce Westerman · HouseBuy · $1,001 - $15,000 · traded 3 Mar 2025 · disclosed 16 Apr 2025
- Daniel Goldman · HouseBuy · $15,001 - $50,000 · traded 6 Mar 2023 · disclosed 17 Apr 2023
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
EW peers
The largest companies in the same industry, then in the same sector.
- NOVO-B.CO Novo Nordisk
- LLY Eli Lilly and Company
- JNJ Johnson & Johnson
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- UNH UnitedHealth Group Incorporated
- NVSEF Novartis AG
- AZN AstraZeneca (ADR)
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Edwards Lifesciences (EW) undervalued?
Against our fair value estimate of $38.48, EW at $86.32 is 55% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own EW?
18 of the institutions we track reported a position in EW in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is EW's P/E ratio?
EW trades at 49.8 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its EW data?
Fundamentals for EW come from company filings and exchange data, as listed on NYSE; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:38 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for EW, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.